Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics.
A three-stage genome-wide association study recently identified single nucleotide polymorphisms (SNPs) in five loci (fibroblast growth receptor 2 (FGFR2), trinucleotide repeat containing 9 (TNRC9), mitogen-activated protein kinase 3 K1 (MAP3K1), 8q24, and lymphocyte-specific protein 1 (LSP1)) associated with breast cancer risk. We investigated whether the associations between these SNPs and breast cancer risk varied by clinically important tumor characteristics in up to 23,039 invasive breast cancer cases and 26,273 controls from 20 studies. We also evaluated their influence on overall survival in 13,527 cases from 13 studies. All participants were of European or Asian origin. rs2981582 in FGFR2 was more strongly related to ER-positive (per-allele OR (95%CI) = 1.31 (1.27-1.36)) than ER-negative (1.08 (1.03-1.14)) disease (P for heterogeneity = 10(-13)). This SNP was also more strongly related to PR-positive, low grade and node positive tumors (P = 10(-5), 10(-8), 0.013, respectively). The association for rs13281615 in 8q24 was stronger for ER-positive, PR-positive, and low grade tumors (P = 0.001, 0.011 and 10(-4), respectively). The differences in the associations between SNPs in FGFR2 and 8q24 and risk by ER and grade remained significant after permutation adjustment for multiple comparisons and after adjustment for other tumor characteristics. Three SNPs (rs2981582, rs3803662, and rs889312) showed weak but significant associations with ER-negative disease, the strongest association being for rs3803662 in TNRC9 (1.14 (1.09-1.21)). rs13281615 in 8q24 was associated with an improvement in survival after diagnosis (per-allele HR = 0.90 (0.83-0.97). The association was attenuated and non-significant after adjusting for known prognostic factors. Our findings show that common genetic variants influence the pathological subtype of breast cancer and provide further support for the hypothesis that ER-positive and ER-negative disease are biologically distinct. Understanding the etiologic heterogeneity of breast cancer may ultimately result in improvements in prevention, early detection, and treatment.
Garcia-Closas
Montserrat
M
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Marylan, United States of America. montse@nih.gov
Hall
Per
P
Nevanlinna
Heli
H
Pooley
Karen
K
Morrison
Jonathan
J
Richesson
Douglas A
DA
Bojesen
Stig E
SE
Nordestgaard
Børge G
BG
Axelsson
Christen K
CK
Arias
Jose I
JI
Milne
Roger L
RL
Ribas
Gloria
G
González-Neira
Anna
A
Benítez
Javier
J
Zamora
Pilar
P
Brauch
Hiltrud
H
Justenhoven
Christina
C
Hamann
Ute
U
Ko
Yon-Dschun
YD
Bruening
Thomas
T
Haas
Susanne
S
Dörk
Thilo
T
Schürmann
Peter
P
Hillemanns
Peter
P
Bogdanova
Natalia
N
Bremer
Michael
M
Karstens
Johann Hinrich
JH
Fagerholm
Rainer
R
Aaltonen
Kirsimari
K
Aittomäki
Kristiina
K
von Smitten
Karl
K
Blomqvist
Carl
C
Mannermaa
Arto
A
Uusitupa
Matti
M
Eskelinen
Matti
M
Tengström
Maria
M
Kosma
Veli-Matti
VM
Kataja
Vesa
V
Chenevix-Trench
Georgia
G
Spurdle
Amanda B
AB
Beesley
Jonathan
J
Chen
Xiaoqing
X
Devilee
Peter
P
van Asperen
Christi J
CJ
Jacobi
Catharina E
CE
Tollenaar
Rob A E M
RA
Huijts
Petra E A
PE
Klijn
Jan G M
JG
Chang-Claude
Jenny
J
Kropp
Silke
S
Slanger
Tracy
T
Flesch-Janys
Dieter
D
Mutschelknauss
Elke
E
Salazar
Ramona
R
Wang-Gohrke
Shan
S
Couch
Fergus
F
Goode
Ellen L
EL
Olson
Janet E
JE
Vachon
Celine
C
Fredericksen
Zachary S
ZS
Giles
Graham G
GG
Baglietto
Laura
L
Severi
Gianluca
G
Hopper
John L
JL
English
Dallas R
DR
Southey
Melissa C
MC
Haiman
Christopher A
CA
Henderson
Brian E
BE
Kolonel
Laurence N
LN
Le Marchand
Loic
L
Stram
Daniel O
DO
Hunter
David J
DJ
Hankinson
Susan E
SE
Cox
David G
DG
Tamimi
Rulla
R
Kraft
Peter
P
Sherman
Mark E
ME
Chanock
Stephen J
SJ
Lissowska
Jolanta
J
Brinton
Louise A
LA
Peplonska
Beata
B
Klijn
Jan G M
JG
Hooning
Maartje J
MJ
Meijers-Heijboer
Han
H
Collee
J Margriet
JM
van den Ouweland
Ans
A
Uitterlinden
Andre G
AG
Liu
Jianjun
J
Lin
Low Yen
LY
Yuqing
Li
L
Humphreys
Keith
K
Czene
Kamila
K
Cox
Angela
A
Balasubramanian
Sabapathy P
SP
Cross
Simon S
SS
Reed
Malcolm W R
MW
Blows
Fiona
F
Driver
Kristy
K
Dunning
Alison
A
Tyrer
Jonathan
J
Ponder
Bruce A J
BA
Sangrajrang
Suleeporn
S
Brennan
Paul
P
McKay
James
J
Odefrey
Fabrice
F
Gabrieau
Valerie
V
Sigurdson
Alice
A
Doody
Michele
M
Struewing
Jeffrey P
JP
Alexander
Bruce
B
Easton
Douglas F
DF
Pharoah
Paul D
PD
D051017:Apoptosis Regulatory Proteins; D001943:Breast Neoplasms / Q000235:genetics* / Q000473:pathology*; D016022:Case-Control Studies; D002898:Chromosomes, Human, Pair 8 / Q000235:genetics; D005260:Female; D020022:Genetic Predisposition to Disease; D006609:High Mobility Group Proteins; D006801:Humans; D015810:Linkage Disequilibrium; D048728:MAP Kinase Kinase Kinase 1 / Q000235:genetics; D008840:Microfilament Proteins / Q000235:genetics; D008875:Middle Aged; D016017:Odds Ratio; D020641:Polymorphism, Single Nucleotide; D051497:Receptor, Fibroblast Growth Factor, Type 2 / Q000235:genetics; D011980:Receptors, Progesterone / Q000235:genetics; D015534:Trans-Activators; D018911:Trinucleotide Repeats
D051017:Apoptosis Regulatory Proteins; D006609:High Mobility Group Proteins; C489183:LSP1 protein, human; D008840:Microfilament Proteins; D011980:Receptors, Progesterone; C521752:TOX3 protein, human; D015534:Trans-Activators; C496353:FGFR2 protein, human; D051497:Receptor, Fibroblast Growth Factor, Type 2; D048728:MAP Kinase Kinase Kinase 1; C482576:MAP3K1 protein, human